Author(s)

Bennett Elzey¹, Sandra Torregrosa-Allen², Peterson Li³, Ben Ramsey², Matthew Shaw^3*

¹Department of Urology, Indiana University School of Medicine, Indianapolis, USA.
²Department of Comparative Pathobiology, Purdue University, West Lafayette, USA.
³Shaw Scientific LLC, Carmel, USA.

We hypothesize that a cylinder implant made of multilayer Poly-lactic-co-glycolic-acid (PLGA) membrane can be a method for controlled and extended drug release. We fashioned a multilayer cylindrical implant termed STID100 that released doxorubicin for 3 weeks in an orthotopic 4T1 breast cancer model in Balb/C mice. This implant starts as a thin doxorubicin-embedded PLGA membrane, and is then rolled into a cylinder containing an air gap between the membrane layers. Its controlled sustained release delivered 2× the amount of the intravenous (IV) equivalent of doxorubicin, inhibited the primary tumor, and prevented lung metastasis. Importantly it did not cause weight loss, splenomegaly, or cardiac toxicity vs systemically administrated doxorubicin. This favorable safety profile is further substantiated by the finding of no detectable plasma doxorubicin in multiple time points during the 3-week period, and low tumor doxorubicin concentration. The implant system delivered to the specification of an ideal pharmacological paradigm might offer a better coverage of the local tumor, significantly preventing metastatic spread with less drug toxicity to many vital organs, compared to the traditional pharmacology of IV route. The profile of STID made it an attractive therapeutic alternative in metastatic tumor prevention, pain management and many other diverse clinical scenarios.

PLGA, Doxorubicin, Implant, Multilayer Membrane, Metastasis, Controlled Release, Extended Release, Polymer, Tumor, Breast Cancer, Mice, Regional Chemotherapy, Pharmacology

Elzey, B. , Torregrosa-Allen, S. , Li, P. , Ramsey, B. and Shaw, M. (2016) A Totally Absorbable Multilayer PLGA Implant Device Containing Doxorubicin Inhibited Tumor Growth and Metastasis without Systemic Toxicity in Murine Breast Cancer and an Ideal Pharmacological Paradigm for Regional Chemotherapy. Journal of Biosciences and Medicines, 4, 66-81. doi: 10.4236/jbm.2016.47008.